In a bid to better understand, and potentially treat, a host of conditions that affect early cognition, neurodevelopment and the brain later in life, investigators at Johns Hopkins Medicine and colleagues throughout the world have been mapping the molecular construction of the human brain. These models, which are supported in part by federal and international research grants, are helping researchers study genetic links and pathways involved in a variety of conditions, ranging from autism spectrum disorder, which affects about 1 in 31, or 3%, of children in the U.S., to Alzheimer’s disease, which is estimated to affect more than 7 million U.S. adults, including 1 in 9, or 11%, age 65 and older.   

To support this blueprint, Carlo Colantuoni, Ph.D., an adjunct professor of neurology at Johns Hopkins Medicine and the Institute for Genome Sciences at the University of Maryland School of Medicine, and other researchers have, in their most recent study, which publishes March 25 in Nature Neuroscience, brought together data from nearly 200 published studies and more than 30 million cells to advance insight about how the neocortex, the outermost layers of the brain, develops and forms over time. This region of the brain is responsible for a variety of functions, including how we think, sense, process and store information, and make decisions.

Researchers have determined how a key protein activates brown fat by expanding blood vessels and nerves in the heat-generating tissue. The findings, published in Nature Communications, point to a potential strategy for treating obesity that deviates from the current approach of suppressing appetite. 

Researchers from the Keck School of Medicine of USC are receiving up to $6.8 million for a two-year research project to develop new computational models and support tools that could accelerate access to cell and gene therapies for children with rare diseases. The team will develop a new framework that combines detailed data about the biological features of each therapy and how patients respond to them. By using artificial intelligence (AI) to study these connections, the project aims to better understand how specific features of a therapy relate to patient outcomes. The research is funded by the Advanced Research Projects Agency for Health (ARPA-H) UNIfying Cell Therapy Outcome prediction and Regulatory Navigation (UNICORN) project, led by ARPA-H Program Manager Daria Fedyukina, Ph.D. UNICORN combines advanced cell analysis technology developed by the team with machine learning tools to identify biological patterns and therapy product features linked to treatment response. This approach aims to enable the development of a regulatory decision-support tool that guides interpretation of product-related evidence when limited data makes conventional measures difficult to establish, enabling patients and families to access new treatments sooner.

Therapeutic solutions available for neurological disorders are limited.  A new review highlights the emerging role of regulatory B cells in immune regulation, focusing on their potential neuroprotective roles and therapeutic implications in these disorders. The review suggests that interleukin 10 secreted by the B cells play an important role in suppressing pro-inflammatory cytokine production. Regulatory B cells can become promising therapeutic targets for future neuroprotective strategies.